122 related articles for article (PubMed ID: 23998443)
21. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach.
Al Hothali GI
Int J Health Sci (Qassim); 2013 Jun; 7(2):220-39. PubMed ID: 24421750
[TBL] [Abstract][Full Text] [Related]
22. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
Guenova E; Hoetzenecker W; Rozati S; Levesque MP; Dummer R; Cozzio A
Expert Opin Investig Drugs; 2014 Apr; 23(4):457-67. PubMed ID: 24397291
[TBL] [Abstract][Full Text] [Related]
23. Pitfalls in the diagnosis of cutaneous lymphoma.
Batrani M; Bhawan J
Am J Dermatopathol; 2014 Jan; 36(1):90-100. PubMed ID: 24366200
[TBL] [Abstract][Full Text] [Related]
24. Altered expression of Bcl-2, c-Myc, H-Ras, K-Ras, and N-Ras does not influence the course of mycosis fungoides.
Maj J; Jankowska-Konsur A; Plomer-Niezgoda E; Sadakierska-Chudy A; Reich A
Arch Med Sci; 2013 Oct; 9(5):895-8. PubMed ID: 24273576
[TBL] [Abstract][Full Text] [Related]
25. Some New Aspects of Genetic Variability in Patients with Cutaneous T-Cell Lymphoma.
Vašků V; Máchal J; Zlámal F; Vašků A
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553668
[TBL] [Abstract][Full Text] [Related]
26. Real-world data on the effectiveness and safety of interferon-alpha-2a intralesional injection for the treatment of focally recalcitrant mycosis fungoides.
Zhang SY; Liu ZR; Yang L; Wang T; Liu J; Liu YH; Fang K
Ann Transl Med; 2020 Aug; 8(15):920. PubMed ID: 32953720
[TBL] [Abstract][Full Text] [Related]
27. A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL).
Tsang M; Gantchev J; Netchiporouk E; Moreau L; Ghazawi FM; Glassman S; Sasseville D; Litvinov IV
Oncotarget; 2018 Dec; 9(102):37647-37661. PubMed ID: 30701021
[TBL] [Abstract][Full Text] [Related]
28. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L; Rodriguez-Pinilla SM; Onaindia A; Ara M; Requena L; Piris MÁ
Haematologica; 2019 Feb; 104(2):226-235. PubMed ID: 30630983
[TBL] [Abstract][Full Text] [Related]
29. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells.
Schcolnik-Cabrera A; Domínguez-Gómez G; Dueñas-González A
Am J Blood Res; 2018; 8(2):5-16. PubMed ID: 30038842
[TBL] [Abstract][Full Text] [Related]
30. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
[TBL] [Abstract][Full Text] [Related]
31. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
Ni X; Zhang X; Hu CH; Langridge T; Tarapore RS; Allen JE; Oster W; Duvic M
Oncotarget; 2017 Sep; 8(37):61761-61776. PubMed ID: 28977902
[TBL] [Abstract][Full Text] [Related]
32. The biomarker landscape in mycosis fungoides and Sézary syndrome.
Dulmage B; Geskin L; Guitart J; Akilov OE
Exp Dermatol; 2017 Aug; 26(8):668-676. PubMed ID: 27897325
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
[TBL] [Abstract][Full Text] [Related]
34. Sézary Syndrome: Clinical and Biological Aspects.
Kohnken R; Fabbro S; Hastings J; Porcu P; Mishra A
Curr Hematol Malig Rep; 2016 Dec; 11(6):468-479. PubMed ID: 27704468
[TBL] [Abstract][Full Text] [Related]
35. Genomic landscape of cutaneous T cell lymphoma.
Choi J; Goh G; Walradt T; Hong BS; Bunick CG; Chen K; Bjornson RD; Maman Y; Wang T; Tordoff J; Carlson K; Overton JD; Liu KJ; Lewis JM; Devine L; Barbarotta L; Foss FM; Subtil A; Vonderheid EC; Edelson RL; Schatz DG; Boggon TJ; Girardi M; Lifton RP
Nat Genet; 2015 Sep; 47(9):1011-9. PubMed ID: 26192916
[TBL] [Abstract][Full Text] [Related]
36. Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma.
Dulmage BO; Story SK; Falo LD; Geskin LJ
Leuk Lymphoma; 2015 Jul; 56(7):2225-7. PubMed ID: 25511681
[No Abstract] [Full Text] [Related]
37. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
38. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma.
Sandoval J; Díaz-Lagares A; Salgado R; Servitje O; Climent F; Ortiz-Romero PL; Pérez-Ferriols A; Garcia-Muret MP; Estrach T; Garcia M; Nonell L; Esteller M; Pujol RM; Espinet B; Gallardo F
J Invest Dermatol; 2015 Apr; 135(4):1128-1137. PubMed ID: 25405321
[TBL] [Abstract][Full Text] [Related]
40. Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.
Litvinov IV; Cordeiro B; Huang Y; Zargham H; Pehr K; Doré MA; Gilbert M; Zhou Y; Kupper TS; Sasseville D
Clin Cancer Res; 2014 Jul; 20(14):3799-808. PubMed ID: 24850846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
